P&G Hygiene & Health Care Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹28,047 Cr
- Book Value
- ₹232
- Stock P/E
- 35.5
- Dividend Yield
- 2.66%
- ROE
- 114.9%
- ROCE
- 157.5%
- PEG Ratio
- 2.44
- EV/EBITDA
- 24.6
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Technical snapshot
EOD ·Procter & Gamble Hygiene & Health Care Ltd closed at ₹8,239.00 on 19 August 2026, down 0.9% on the day, 6.4% below its 50-day average, 43.2% below its 52-week high, with volume at 0.39× its 20-session average.
- RSI 14
- 27.2
- vs 50-day SMA
- -6.4%
- vs 200-day SMA
- -22.9%
- From 52-week high
- -43.2%
- Relative volume
- 0.39×
- 20-day return
- -8.5%
End-of-day prices from exchange-published files (NSE/BSE bhavcopy), updated after market close. Descriptive statistics, not investment advice.
P&G Hygiene & Health Care share price today
P&G Hygiene & Health Care (NSE: PGHH) owns two categories outright: Whisper defines feminine hygiene in India, Vicks defines cold-and-cough care — brands so synonymous with their categories that the product name is the category name in most households. The capital efficiency is the highest among India’s FMCG listings, and it isn’t close: 157.5% ROCE, 114.9% ROE, zero debt, with a 2.66% dividend shipping the surplus out.
Growth is the honest constraint — 7.4% five-year sales CAGR reflects category maturity in urban markets — while the penetration story (feminine hygiene usage across Bharat remains far below saturation) grinds forward. At 35.5×, much of the business’s exceptional quality is already recognised.
Two category kings, one tiny balance sheet
Whisper’s moat compounds through taboo-breaking marketing that competitors must free-ride or match, retail depth into kirana counters, and product laddering from value to premium. Vicks is winter’s annuity — a century-old brand whose habit formation no challenger has dented. Both need almost no capital: manufacturing is compact, brands are amortised history, and P&G’s shared distribution muscle carries the rest — hence return ratios that read like typos.
What matters next: penetration-led volume growth (the whole thesis), competitive intensity in feminine hygiene’s value tier, parent royalty rates (periodically raised, periodically contested), and rural consumption cycles.
The numbers
Financial snapshot — 5 August 2026
| Metric | Value |
|---|---|
| Market cap | ₹28,047 Cr |
| P/E (TTM) | 35.5 |
| EV/EBITDA | 24.6 |
| Operating margin | 25.3% |
| ROE / ROCE | 114.9% / 157.5% |
| Debt to equity | 0.00 |
| Sales CAGR (5y) | 7.4% |
| Profit CAGR (5y) | 14.5% |
| Promoter holding | 70.6% |
| EPS (TTM) | ₹243.6 |
P&G Hygiene share price target 2026 to 2030
EPS base ₹243.6 (TTM). Bear: category maturity wins — 6% growth, multiple at 26×. Base: penetration grinds, margins mix up — 11% growth at 32×. Bull: rural adoption accelerates the curve — 15% growth at 40×.
From ₹8,640, the base case is ≈ +52% over four and a half years plus the 2.66% yield; the bear is −2%. The range reflects extraordinary capital efficiency constrained by a mature sales-growth rate.
What supports the case
- 157% ROCE — India’s capital-efficiency champion among consumer listings.
- Whisper and Vicks are category-defining brands with generational habit moats.
- A 2.66% yield from a business that cannot spend its own cash.
- Feminine-hygiene penetration is a decade-length volume runway.
- Zero debt, MNC governance, and pricing power inflation keeps validating.
The risks: single-digit sales growth is the structural ceiling until penetration inflects, value-tier competition presses Whisper’s entry price points, and royalty escalations recur as a minority-shareholder theme.
What to weigh at the current price
The tension is whether feminine-hygiene penetration can lift volume growth before royalty changes or value-tier competition make 35.5× earnings harder to defend.
FAQ
What is the PGHH share price target for 2030? The table above sets out bear, base and bull scenarios for each year to 2030. They are valuation sensitivities, not promised prices.
How is 157% ROCE possible? Almost no capital employed: brands built decades ago, compact manufacturing, distribution shared with the P&G group. Large profits over a tiny capital base produce extraordinary ratios.
Where does growth come from if categories are mature? Penetration (feminine hygiene usage outside metros is still far from universal), premiumisation (product laddering), and pricing — a grind, not a sprint, which the multiple must respect.
When are PGHH’s next results? Check the results calendar and confirm the announced date in the relevant exchange filing.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.